Loading
A phase 2 trial of IMC-001 in advanced solid tumours, run by ImmuneOncia Therapeutics Inc., now recruiting.
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor is a phase 2 interventional study registered as NCT06365840 by ImmuneOncia Therapeutics Inc., with 30 participants planned, started 2025-01-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: IMC-001.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/